BI-PARTISAN BILLS
SUPPORTING DIVERSITY IN CLINICAL TRIALS
Your support for bills promoting diversity in clinical trails will help promote health equity, counter racial biases, and ensure that medications, therapies, and devices work well for people of many different backgrounds in our diverse communities.
Rep. Diana DeGette (D-CO)
Rep. Fred Upton (R-MI)
Rep. Anna G. Eshoo (D-CA)
Rep. Brian Fitzpatrick (R-PA)
Bob Menendez (D-N.J.)
Tim Scott (R-S.C.)
The Cures 2.0 Act is legislation focused on increasing the speed of delivering groundbreaking, new – and potentially lifesaving – cures, treatments, and innovations to communities most in need.
The Cures 2.0 Act would create a new agency aimed at ending difficult diseases – like cancer, diabetes, ALS, Alzheimer’s and others. The “Advanced Research Projects Agency for Health” or ARPA-H, would be housed in the National Institutes of Health with the mission of finding cures and treatments for illnesses that affect a significant number of Americans. The ARPA-H will bring together some of our nation’s greatest minds with the full weight of the federal government behind the effort to end these terrible illnesses.
The Diverse and Equitable Participation in Clinical Trials (DEPICT) Act is legislation focused on increasing diversity in clinical trials.
Clinical trial participants should reflect those individuals most likely to consume the product, presently this is not the case. Historical inequities in health and research among racial and ethnic minorities need to be addressed. The Act would require enhanced data reporting on clinical trial demographics and provide resources, like workshops and grants, to improve access to clinical trials. Robust representation improves the ability to generate knowledge of potential treatments and health products for all Americans.
The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Act is important legislation for underrepresented populations to seek better health outcomes through access and education about clinical trials.
The DIVERSE Trials Act would allow the U.S. Department of Health and Human Services (HHS) to issue grant funding or contracts to organizations in the support of increasing education, community outreach and recruitment for clinical trials. The DIVERSE Trials Act provides an opportunity for historically medically marginalized communities to seek better health outcomes for diseases where they are disproportionately impacted.